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The protein kinase C-θ (PKCθ), which is essential for T cell function and survival, is also
required for efficient anti-tumor immune surveillance. Natural killer (NK) cells, which express
PKCθ, play a prominent role in this process, mainly by elimination of tumor cells with
reduced or absent major histocompatibility complex class-I (MHC-I) expression. This justi-
fies the increased interest of the use of activated NK cells in anti-tumor immunotherapy in
the clinic. The in vivo development of MHC-I-deficient tumors is much favored in PKCθ−/−
mice compared with wild-type mice. Recent data offer some clues on the mechanism
that could explain the important role of PKCθ in NK cell-mediated anti-tumor immune
surveillance: some studies show that PKCθ is implicated in signal transduction and anti-
tumoral activity of NK cells elicited by interleukin (IL)-12 or IL-15, while others show that it
is implicated in NK cell functional activation mediated by certain killer-activating receptors.
Alternatively, the possibility that PKCθ is involved in NK cell degranulation is discussed,
since recent data indicate that it is implicated in microtubule-organizing center polarization
to the immune synapse in CD4+ T cells. The implication of PKC isoforms in degranulation
has been more extensively studied in cytotoxic T lymphocyte, and these studies will be
also summarized.
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PKCθ IN T CELLS
The protein kinase C-θ (PKC-θ) was initially isolated as a PKC
isoform expressed in T cells (Baier et al., 1993), although it was
demonstrated afterward that its expression was not restricted to
them (Isakov and Altman, 2002). Structurally, PKCθ is a mem-
ber of the novel, Ca2+-independent, PKC subfamily (which also
includes PKCδ, ε, and η). PKCθ rapidly translocated to the
immunological synapse (IS), suggesting a central role in T lympho-
cyte signal transduction (Monks et al., 1997). Seminal discoveries
by the group of Amnon Altman demonstrated that PKCθ was
indeed essential in T cell activation through the triggering of key
transcription factors such as AP-1 (activating protein-1; Baier-
Bitterlich et al., 1996), nuclear factor-κB (NF-κB; Coudronniere
et al., 2000), and nuclear factor of activated T cell (NF-AT; Alt-
man et al., 2004). This was confirmed by two independent groups
who developed two different strategies to knockout PKCθ mice
(Sun et al., 2000; Pfeifhofer et al., 2003). These transcription
factors control the expression of target genes implicated in pro-
liferation, survival, and/or cytotoxicity. One of them, Fas Ligand
(FasL), is also implicated in immune homeostasis maintenance
through activation-induced cell death (AICD). PKCθ deficient
mice show normal lymphocyte development but display a selec-
tive phenotype in their mature T cell compartment, characterized
by impaired proliferation and interleukin (IL)-2 production in
response to T cell receptor (TCR)/CD28 co-stimulation (Sun et al.,
2000; Pfeifhofer et al., 2003). This phenotype is also linked to
the regulation of genes essential for survival, such as B-cell lym-
phoma (Bcl)-2 family members (Bertolotto et al., 2000; Villalba
et al., 2001b; Barouch-Bentov et al., 2005). The mechanism by
which PKCθ contributes to the first steps of T cell activation has
recently been uncovered. A motif in the V3 domain determines
its localization to the IS through the direct interaction with the
co-stimulation molecule CD28 (Kong et al., 2011). Other experts
in this issue extensively describe the biochemical and functional
aspects of PKCθ regulation in T cells.
NATURAL KILLER CELLS
The appearance of clinically detectable tumors may be the result of
the proliferation of cells that have developed sophisticated strate-
gies to escape the immune response. Arguably, the most relevant
is the total or selective loss of expression of the major histocom-
patibility complex class-I (MHC-I). MHC-I, known as human
leukocyte antigen (HLA) in humans, mediates self-recognition
and thus present endogenously synthesized antigens to CD8+
cytotoxic T lymphocytes (CTLs). Changes in MHC-I allow tumor
cells to avoid CTLs and thereby the adaptive immune response
(Aptsiauri et al., 2007). However, a small amount of surface MHC-
I must be maintained, because its absence would make tumor cells
targets of natural killer (NK) cells.
Natural killer cells are members of the innate immune system
with natural cytotoxicity against tumor cells. This lymphocyte
lineage produces cytokines and shows cytotoxicity and effector
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functions (Lanier, 2008; Velardi, 2008). NK cells predominantly
target cells lacking MHC-I, which include transformed or virus-
infected cells, which down-regulate MHC-I expression to avoid
recognition by CTLs. Therefore the “missing self” hypothesis pro-
poses that NK cells discriminate target cells from other healthy
“self” cells based on MHC-I expression. However, it is now
clear that NK cell activation depends on a complex signaling
process mediated by activating and inhibitory receptors, being
the functional outcome the final result of the different activating
and inhibitory signals received (see the schematic representation
shown in Figure 1).
One of the most potent activating NK cell receptor (killer-
activating receptor, KAR) is CD16, a receptor for the Fc domain
of IgG, also termed FcγRIII, which is responsible for antibody-
dependent cell-mediated cytotoxicity (ADCC), one of the main
physiological functions of NK cells. CD16 signals through its asso-
ciation with the immunoreceptor tyrosine-based activation motif
(ITAM)-containing adaptors FcεR1γ and CD3ζ, which finally acti-
vate ZAP-70 and Syk protein tyrosine kinases (López-Botet et al.,
2000; Lanier, 2008; KEGGpathway, 2011). Other human KARs
that share a similar signal transduction machinery are NKp46 and
NKp30. Influenza virus hemagglutinin (HA) and B7-H6 expressed
on the surface of tumors, respectively, have been identified as lig-
ands for these KAR, but it is also possible that other unidentified
endogenous ligands exist.
NKp44, which ligand is also unknown, completes, together with
NKp30 and NKp46, the so-called natural cytotoxicity receptors
(NCR) family. However, NKp44 signals through a different ITAM-
containing adaptor, DAP12, that also results in the activation of
ZAP-70 and Syk. This signaling adaptor is shared by several acti-
vating receptors belonging to the killer cell immunoglobulin-like
receptors (KIR) family: KIR2DS1 and KIR2DS4, which ligands
are specific haplotypes of HLA-C, and KIR2DS2 and KIR3DS1,
which ligands are still unknown. Finally, the DAP12 adaptor is
also used by NKG2C, a member of a different family of NK
cell receptors, the C-lectin type family. This activating recep-
tor is expressed as a heterodimer with CD94 and its ligand is
HLA-E.
FIGURE 1 | Schematic representation of the balance between
activating (AR) and inhibitory receptors (IR) in NK cell anti-tumoral
function. Receptors for MHC-I can be either inhibitory or activating. The
expression levels of MHC-I or of the different ligands for the activating
receptors on the target cell is of paramount importance in the final
response. The final outcome between both types of signaling will
determine if there is a cytotoxic response or not.
Another activating receptor of the C-lectin type is NKG2D.
This protein is expressed as a homodimer, and uses a differ-
ent adaptor for signaling, DAP10. This adaptor does not contain
ITAM domains in its cytoplasmic tail, but it contains one YINM
motif, that, upon tyrosine phosphorylation recruits both PI3K and
the Grb2-Vav1-Sos1 complex. The downstream signaling of this
receptor does not require ZAP-70 and/or Syk activation, but results
also in ERK and PKC activation. NKG2D ligands in humans are
members of the MIC and ULBP families of proteins, which are
expressed by virus-infected or tumoral cells.
Another family of activating receptors is the SLAM family,
which includes CD244 (also known as 2B4), CRACC (CD319),
and NTB-A. CD244 ligand is CD48, while CRACC and NTB-A
promote homophilic interactions. These receptors posses TIYXX
motifs in their cytoplasmic tails (also called immunoreceptor
tyrosine-based switch motif, ITSM), which, upon tyrosine phos-
phorylation recruit the adaptors SAP or EAT2. If SAP is recruited,
then the signals generated, including the activation of the pro-
tein tyrosine kinase Fyn, result in activation. However, if EAT2 is
recruited, then signals are rather inhibitory.
Finally, two other activating receptors are expressed in human
NK cells, DNAM-1, also known as CD226, and NKp80, also known
as CLEC5C. It seems that DNAM-1 signaling is dependent on spe-
cific domains present in its own cytoplasmic tail (Shibuya et al.,
1998). On the other hand, it has been recently demonstrated that
NKp80 transmits signals through a semi-ITAM domain present in
its cytoplasmic tail, activating directly Syk (Dennehy et al., 2011).
The ligands for DNAM-1 are CD112 and CD155, molecules impli-
cated in leukocyte adhesion, and the ligand for NKp80 is AICL, a
very close homolog to NKp80 expressed on the surface of solid
tumors.
In mice, NK cell activating receptors belong rather to the C-
lectin family, normally forming homodimers on the surface of NK
cells, and transmitting signals through the DAP12 adaptor. These
are Ly49D, Ly49H, and Ly49P, which ligands are, respectively, H-
2Dd and murine cytomegalovirus antigens. Two other members of
this family, NK1.1 and NKR-P1F signals instead through FcεR1γ
and recognize members of a new C-type lectin-related (Clr) family.
PILRβ has been identified as an activating NK cell receptor in
mice, being its signaling dependent also on DAP12 and its ligand
CD99.
Activating NK cell receptors used by mice and humans include
CD16, CD244, the heterodimer CD94/NKG2C, the homodimer
NKG2D, and DNAM-1.
Inhibitory NK cell receptors posses ITIM domains in their
cytoplasmic tails, and its ligation results in activation of protein
tyrosine phosphatases, mainly SHP-1 and SHP-2, that counter-
act the signals given by activating receptors, initiated by tyrosine
phosphorylation.
Most of the killer cell immunoglobulin-like receptors (KIR)
have inhibitory activity, being their ligands specific or broad
HLA haplotypes. Among them, KIR2DL1 recognizes HLA-Cw4
and related, “group2” alleles. KIR2DL2 and KIR2DL3 rec-
ognize HLA-Cw3 and related, “group1” alleles. KIR3DL1 is
the receptor for HLA-B allotypes with Bw4 motifs. Finally,
KIR3DL2 is the receptor for HLA-A3/11 and KIR2DL5 ligands
are unknown.
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Some members of the C-lectin type family of NK cell receptors
are inhibitory. These are the heterodimer CD94/NKG2A, which
ligand is HLA-E,and the homodimers Mafa and NKR-P1 (CD161),
which ligands, are, respectively, cadherins and lectin-like transcript
1 (LLT1), respectively.
Other human NK cell inhibitory receptors are immunoglobulin-
like transcript 2 (ILT2), which binds to most HLA-I haplotypes;
LAIR-1, which binds to collagen; CEACAM-1, that binds to the
different CD66 variants; and SIGLEC7, that binds to sialic acids.
Finally, KIR2DL4 (CD158d) is a member of the KIR family,
which ligand is the non-classical HLA protein HLA-G, that has
both activating and inhibitory capacities, similar to the described
situation with CD244 (2B4).
Again, most of the inhibitory receptors in mouse NK cells
belong to the C-type lectin family, Ly49a, c, e, f, g, and i which
ligands are different MHC-I haplotypes (see Table 1 for the spe-
cific ligands of each receptor). Other inhibitory receptors in mouse
NK cells are gp49b1, that binds to integrins, and PILRα, which lig-
and is CD99. Inhibitory receptors shared by mouse and human
NK cells are Mafa, CD94/NKG2A, and LAIR-1. See Table 1 for a
summary of all receptors, ligands, and adaptors.
NK CELLS IN TUMOR IMMUNOTHERAPY
A large interest in NK cells is currently coming from the field of
cancer immunotherapy, which tries to increase the anti-tumoral
immune response of cancer patients. Data from several laborato-
ries suggest that exploiting NK cell alloreactivity could be largely
beneficial independently of the NK cell source for the treatment
of blood-borne cancers (Terme et al., 2008; Velardi, 2008; Cho
and Campana, 2009). Donor-versus-recipient NK cell reactivity is
mediated by KIRs, which sense missing expression of donor KIR-
ligand(s) in the recipient and mediate alloreactions. KIR-ligand
mismatching is a prerequisite for NK cell alloreactivity because in
20 donor–recipient pairs that were not KIR-ligand mismatched in
the graft-versus-host direction, no donor alloreactive NK clones
were found (Ruggeri et al., 2007b).
The most advanced clinical use of NK cells is related to hema-
tological cancers in which current clinical protocols fail inducing
Table 1 | Natural killer cell activating and inhibitory receptors in mice and humans and their ligands.
Adaptor Activating receptor Ligand Inhibitory receptor Ligand
HUMANAND MOUSE
FcεRIγ, CD3ζ CD16 IgG CD94-NKG2A HLA-E (Qa1b)
NKp46 HA, ? Mafa Cadherins
DAP12 CD94-NKG2C HLA-E (Qa1b) LAIR-1 Collagen
DAP10 NKG2D MIC, ULBP (Rae-1, H60)
SAP/EAT2 CD244 (2B4)* CD48
– DNAM-1 CD112, CD155
HUMAN
FcεRIγ, CD3ζ NKp30 B7-H6, ? KIR2DL1 HLA-Cw4
KIR2DL2 HLA-Cw3
KIR2DL3 HLA-Cw3
DAP12 NKp44 ? KIR3DL1 HLA-Bw4
KIR2DS1 HLA-Cw3 KIR3DL2 HLA-A3/11
KIR2DS2 ? KIR2DL5 ?
KIR2DS4 HLA-Cw4 NKR-P1 (CD161) LLT1
KIR3DS1 ? ILT2 HLA-I
FcεRIγ KIR2DL4* HLA-G CEACAM-1 CD66
SAP/EAT2 CRACC* CRACC SIGLEC7 Sialic acids
NTB-A* NTB-A
– NKp80 AICL
MOUSE
DAP12 Ly49D H-2Dd Ly49a H-2Dd, -Dk
Ly49H MCMVm157 Ly49c H-2Kb, -Kd, -Dd, -Dk
Ly49P MCMV?
PILRβ CD99 Ly49e ?
FcεRIγ NK1.1 Clr? Ly49f H-2d
NKR-P1F Clrg Ly49g H-2Dd
Ly49i H-2Dk
gp49b1 Integrins
PILRα CD99
The adaptors used by each family of activating receptors are also indicated. In the mouse and human activating receptor ligand row, parenthesis indicates the mouse
ligand. *Indicates receptors with both activating and inhibitory capabilities. ?, Unknown ligand.
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long-term survival in a significant number of patients. Those
refractory to standard treatment, i.e., radio- and/or chemother-
apy are often subjected to a myeloablative regimen followed by
allogenic hematopoietic stem cell transplantation (HSCT). How-
ever, the mortality linked to this treatment approaches to 20%. In
addition, Graft-versus-Host (GvH) and HvG diseases and oppor-
tunistic infections hamper this procedure. Moreover, relapse has
become the leading cause of death following allogenic HSCT: the
relapse rate has not decreased over the past 20 years (Kroger, 2011).
In general, prognosis is poor for patients who relapsed to an allo-
graft since effective treatment options are limited. These include
donor lymphocyte infusions, withdrawal of immunosuppressive
medication and second allogeneic HSCT. However, new specific
cellular approaches are under investigation. In particular, the use
of alloreactive NK cells after umbilical cord blood transplanta-
tion (UCBT) seems promising. KIR-ligand incompatibility in the
GvH direction improves outcomes after UCBT in the clinic (Stern
et al., 2008; Willemze et al., 2009). Moreover, NK cells: (1) are not
responsible of GvHD; (2) can be injected as “differentiated” cells
without the need of long time survival on patients body; (3) pro-
tect from opportunist infections (Willemze et al., 2009), probably
through their immunoregulatory effects on B cells, T cells and
macrophages, and more importantly on polymorphonuclear cells
(PMNs; Bhatnagar et al., 2010). Finally, NK cell-mediated therapy
after hematopoietic cell transplantation seems safe (Miller et al.,
2005; Ruggeri et al., 2007a; Rubnitz et al., 2010). Immunotherapy,
in particular NK cell-mediated, is probably the only approach to
eliminate these highly resistant tumor cells.
In vitro studies on primary lympho-hematopoietic lineage
tumor cells showed that alloreactive NK cells kill acute and
chronic myeloid leukemia, as well as T cell acute lymphoblastic
leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin’s
lymphoma, and multiple myeloma. The only non-susceptible tar-
get was common ALL, however, KIR-ligand incompatibility in the
GvH direction improves outcomes after UCBT in ALL patients.
Despite their source, alloreactive NK cells home to lympho-
hematopoietic sites and ablate recipient lympho-hematopoietic
cells, including leukemic cells, while sparing other healthy organs.
This explains why NK cells immunotherapy would be mainly use-
ful in blood-borne cancers (Stern et al., 2008; Willemze et al.,
2009).
New strategies are being developed to use NK cells in the
treatment of solid tumors in the clinic. Several tumor-targeted
monoclonal antibodies (mAbs) are included in the clinical care
for certain tumors. Besides inducing antibody-dependent cell-
mediated cytotoxicity (ADCC), these mAbs can kill their targets
through activation of the complement,which in certain cases could
be associated to clinical toxicity, i.e., anti-GD2 therapy (Sorkin
et al., 2010). Nowadays the clinical use of mAbs tries to mainly
exploit ADCC, which induces a more satisfactory clinical response
and is mainly mediated by NK cells in vivo (Alderson and Sondel,
2011). Between the several activating or inhibitory Fc receptors
for IgG (FcγR), NK cells express almost exclusively the activating
FcγRIIIa (CD16). The importance of this receptor in the clinic is
highlighted by the fact that patients with a valine at position 158
of FcγRIIIa (FcγRIIIa158v) respond better to mAbs-mediated ther-
apy. This is linked to the higher affinity for IgG of FcγRIIIa158v NK
cells, leading to a more sensitivity activating receptor and increase
ADCC (Alderson and Sondel, 2011).
PKCθ IN NK CELLS
Compared to T cells, much less is known about the role of PKCθ
in NK cells. PKCθ is expressed in NK cells (Balogh et al., 1999;
Vyas et al., 2002b) and it has been demonstrated that it mediates
the phosphorylation of WASP-interacting protein (WIP) during
NK cell activation (Krzewski et al., 2006). In addition, it has been
shown that PKCθ translocates to the IS during NK recognition of
target cells (Davis et al., 1999).
It was shown that NK cells from PKCθ deficient mice had
impaired IL-12-stimulated interferon (IFN)-γ production, with-
out affecting their cytotoxic potential on YAC-1 cells (Page et al.,
2008), which are extremely sensitive to NK cells, including naïve,
ex vivo obtained, NK cells. However, in a different study (Tassi
et al., 2008), no effect of PKCθ deficiency was observed on IFN-
γ secretion induced by IL-12, IL-18, or a combination of both
cytokines. In this study no effect of PKCθ deficiency was either
observed on cytotoxicity against YAC-1 cells or against tumoral
cells over-expressing KAR ligands (Tassi et al., 2008). It is also pos-
sible that the protocol used to generate NK cells, ex vivo culture in
the presence of IL-2, may have masked the effect of PKCθ during
the cellular cytotoxicity assays, since the tumor cells used in that
study are especially sensitive to NK cells (Van den Broek et al.,
1995; Screpanti et al., 2001; Pardo et al., 2002). Nevertheless, PKCθ
was required to induce IFN-γ and TNF-α secretion by KAR that
contain ITAMs such as NK1.1 and Ly49D. Finally, the early con-
trol of murine cytomegalovirus infection, that is dependent on NK
cell activity, was not affected by the absence of PKCθ (Tassi et al.,
2008).
In human γδ T cells the co-stimulation mediated by NKG2D
was dependent on PKCθ (Nedellec et al., 2010). However, this study
mostly relies on the use of the PKCθ inhibitor rottlerin, which has
been shown to also inhibit other cellular kinases (Davies et al.,
2000).
In addition, our group has demonstrated that PKCθ plays a
prominent role in tumor immune surveillance mediated by NK
cells (see below, Aguiló et al., 2009).
PKCθ IN ANTI-TUMOR IMMUNE SURVEILLANCE
The cancer immuno-surveillance hypothesis proposes that the
immune system detects and eliminates cells undergoing tumor
transformation. Immuno-deficient mice develop more tumors
than immuno-competent mice and clinical data support the
notion that cancer immuno-surveillance also occurs in humans
(Dunn et al., 2002, 2006; Aptsiauri et al., 2007). In addition, the
adaptive immune system is thought to maintain small cancer
lesions in an equilibrium state (Koebel et al., 2007; Melief, 2007).
Therefore, the relevant cellular effectors of immuno-surveillance
must perform two critical tasks to eradicate developing tumors:
directly kill tumor cells and produce cytokines such as IFN-γ to
stimulate the host immune response (Dunn et al., 2006).
We tested the role of PKCθ in T cell leukemia progression by
inducing the disease in wild-type (wt ) and PKCθ-deficient mice
with moloney murine leukemia virus (M-MuLV). In line with
the above-mentioned studies, we found that disease incidence
Frontiers in Immunology | T Cell Biology July 2012 | Volume 3 | Article 187 | 4
Anel et al. PKC-θ in NK cell function
and onset were enhanced in PKCθ−/− mice. Transfer of leukemic
T cells from wt donors into PKCθ-deficient and wt recipients
induced leukemia in 100 and 40% of the mice, respectively. Inter-
estingly, leukemic cells from PKCθ−/− donors were less efficient
at forming tumor since only 50% of the PKCθ-deficient and
10% of the wt recipients developed the disease. Consistent with
these observations, intravenous injection of low numbers of the
murine lymphoma T cell line EL4 induced tumors more rapidly
in PKCθ−/− mice compared to their wt counterpart. These results
showed that PKCθ was essential for the immune response to
leukemia in mice. This response probably involved CTL func-
tion, since both M-MuLV-induced tumors and EL4 cells expressed
MHC-I (Garaude et al., 2008). These results also suggest a role of
PKCθ in cancer immune surveillance, since tumors generated in
the absence of this protein were less aggressive than those gener-
ated in the presence of PKCθ. In this connection, it has been also
described that PKCθ, by mediating the activation of NF-κB by pre-
TCR in immature thymocytes, contributes to the development of
Notch3-dependent T cell lymphoma (Felli et al., 2005). This indi-
cates that PKCθ could be somehow required for lymphoma cell
“fitness,” and the results obtained in PKCθ−/− mice could reflect
both effects.
Cells of the innate immune system (γδ T, NK, and NK T
cells) can also mediate anti-tumor responses. Specifically, NK cells
play an important role in tumor immune surveillance (Ljung-
gren and Karre, 1985; Terme et al., 2008; Vivier et al., 2008),
as they control progression of MHC-I-deficient tumors using
perforin/granzyme- and FasL-mediated cytotoxicity (Van den
Broek et al., 1995; Screpanti et al., 2001; Pardo et al., 2002). More-
over, NK cells also function as mediators between innate and
adaptive immunity in anti-tumor responses (Moretta et al., 2008).
Since most tumors cells down-regulate MHC-I expression to
escape the CTL-mediated response (Garrido et al., 2010), it is
important to study the role of NK cells in this context.
The in vivo development of a MHC-I-deficient tumor (RMA-
S) is favored in PKCθ−/− mice compared with wild-type mice
(Aguiló et al., 2009). Previous studies clearly demonstrated that
the in vivo development of this tumor is not dependent on T
cells and that it is controlled by NK cell activity (Kärre et al., 1986;
Smyth et al., 1998, 2000; Kelly et al., 2002; Vosshenrich et al., 2005).
The enhanced tumor growth in PKCθ−/−mice was associated with
a deficient recruitment of NK cells to the site of tumor develop-
ment and with a decreased activation status of recruited NK cells.
This correlated with a reduced ex vivo cytotoxic potential of NK
cells isolated from PKCθ−/− mice on RMA-S cells after poly I:C
treatment (Aguiló et al., 2009). Interestingly, and confirming pre-
vious data (Page et al., 2008; Tassi et al., 2008), no difference was
observed on the killing of YAC-1 cells suggesting that in addition to
the absence of MHC-I, other regulatory events might be required
for the tight control of NK cytotoxicity. YAC-1 cells are sensitive to
naïve NK cells and are not able to induce tumors in syngeneic
mice because of their extreme sensitivity to NK cell-mediated
lysis, mediated by both perforin/granzymes and FasL (Aguiló et al.,
2009). However, NK cells do not target RMA-S cells unless they
are previously activated, i.e., by in vivo injection of poly I:C. Inter-
estingly, only perforin/granzymes, but not FasL, are responsible
for the elimination of RMA-S cells mediated by activated NK cells
(Pardo et al., 2002; Aguiló et al., 2009). Adoptive transfer of naïve
NK cells from wt or PKCθ−/− mice to PKCθ−/− mice was also
performed to demonstrate that the defect in activation was intrin-
sic to NK cells, and not due to any other cellular component.
Hence, PKCθ seems to be implicated in NK cell-mediated anti-
tumor immunity at least by acting on the cytolytic potential of
activated NK cells.
Poly I:C has been extensively used as an indirect in vivo NK
cell activator, through the secretion of cytokines by macrophages
and/or dendritic cells (Djeu et al., 1979). Poly I:C, mimics viral
double-stranded RNA, and is recognized by the member of the
Toll-like receptor family TLR3, which is expressed by antigen-
presenting cells (Alexopoulou et al., 2001), and also by cytosolic
receptors such as MDA5 and RIG-I (Kato et al., 2006). Poly I:C
treatment increased the level of expression and the activation sta-
tus of PKCθ in NK cells, both in vivo and in vitro. In the latter case,
the presence of the whole splenocyte population was needed, being
the effect presumably mediated by macrophages and/or dendritic
cells (Aguiló et al., 2009). This was in agreement with previous
studies demonstrating the increase in anti-tumor activity of NK
cells activated by poly I:C (Akazawa et al., 2007). The increase
in PKCθ expression depended on cell-to-cell contact, while its
activation was mediated by a soluble factor. This soluble factor
should be one of the cytokines secreted by macrophages and/or
DCs that are known to activate NK cells. Since IL-12 signal trans-
duction was reported to be affected in NK cells from PKCθ−/−
mice (Page et al., 2008), this cytokine was tested first. IL-15 was
also included in those studies, since it is important in regulating
NK cell function and survival (Carson et al., 1994; Cooper et al.,
2002), and for efficient anti-tumoral NK cell activity (Liu et al.,
2012). Indeed, both, IL-12 and IL-15, activated PKCθ in NK cells,
with IL-15 being more potent at inducing PKCθ phosphorylation.
More importantly, neutralizing antibodies to IL-15, but not those
blocking IL-12, reduced substantially NK cell PKCθ phosphoryla-
tion induced in vitro by poly I:C treatment of a mixed splenocyte
population (Aguiló et al., 2009). How could IL-15 be coupled to
PKCθ activation? Interestingly, PKCθ is the only T cell expressed
PKC isoform that is activated through a PI3K-dependent path-
way, which is also activated by TCR ligation (Villalba et al., 2002).
Although the main signaling pathway elicited by cytokine recep-
tors is mediated by JAK and STATs, cytokines such as IL-2 are
also able to activate the PI3K pathway (Brennan et al., 1997). It
is interesting to note that IL-2 and IL-15 share the same signaling
receptors suggesting that IL-15 could also trigger the PI3K path-
way, as has been suggested in some studies in T cells (Ben Ahmed
et al., 2009).
Therefore, IL-15 looked as a very feasible candidate to be a
mediator in PKCθ-dependent anti-tumoral NK cell activation.
We have performed additional experiments, analyzing the effect
of IL-15 on different NK cell functions. We have found that,
although IL-15 is able to signal through PKCθ, this signaling
is not needed for the main functional effects of IL-15 on NK
cells (Aguiló et al., in preparation). Hence, IL-15 probably is
not the main cytokine implicated in PKCθ-dependent NK cell
anti-tumoral activity. Additional experiments will be required to
uncover cytokines that mediate dendritic cell-mediated NK cell
activation.
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As a summary (Figure 2), we propose that poly I:C, through
TLR3 activation on macrophages or dendritic cells, elicits the
secretion of cytokines that activate NK cells, including IL-15. Dur-
ing tumor development, danger signals are generated that activate
antigen-presenting cells, which in turn ensure tumor antigen pre-
sentation and secrete a set of cytokines that regulate NK cells.
Some of these cytokines may signal through PKCθ to control NK
cell activation. This activated state is needed to counteract the
growing of MHC-I negative tumors such as RMA-S, while other
tumors, extremely sensitive to NK cell-mediated cytotoxicity, such
as YAC-1, do not grow in syngenic mice. Once KARs are activated
through the ligands expressed on tumoral cells, activated NK cells
would be able to eliminate the tumor in a defined cytokine envi-
ronment. On the other hand, KAR ligation induces the NK cell
secretion of TNF-α and IFN-γ from activated NK cells, a process in
which PKCθ is implicated (Tassi et al., 2008). TNF-α is important
for the recruitment of more NK cells to the tumor environment
(Smyth et al., 1998), which could explain the reduced recruitment
of NK cells observed in PKCθ−/− mice (Aguiló et al., 2009).
A ROLE FOR PKCθ IN NK CELL DEGRANULATION?
Natural killer cells from PKCθ−/− mice had a reduced capacity
to degranulate against RMA-S cells, which correlated with the
impairment in their lytic ability (Aguiló et al., 2009). It has been
recently shown that PKC-θ, together with other members of the
novel PKC family, is implicated in the formation of the IS in CD4+
T cells, probably through a function in microtubule-organizing
center (MTOC) polarization (Quann et al., 2011). However, this
study did not address the possible involvement of this mechanism
in lytic granule secretion and on cytotoxicity.
IMMUNOLOGICAL SYNAPSE FORMATION
Most of the studies performed to determine the relevant molecular
components in lytic granule secretion have been realized on CTL.
The IS of CTL is quite distinct from that of CD4+ T cells since
it should allow both signaling and degranulation. The description
of the CTL immune synapse showed the presence of a “cleft” that
allowed the secretion of lytic granules components (Stinchcombe
et al., 2001b). Hence, the signaling regulating synapse formation
could be different in CD4+ and CD8+ T cells, and even if this sig-
naling is shared, the regulation of lytic granule secretion should be
particular to cytotoxic cells (CTL and NK cells). At the functional
level, not all cytokines are secreted into the synapse of CD4+ T
cells: IL-2 and IFN-γ follow a synapse-mediated secretion, while
TNF-α and some chemokines do not follow a directional type of
secretion (Huse et al., 2006). On the other hand, cytokine release
and degranulation proceed by different pathways also in NK cells
(Reefman et al., 2010).
The IS of NK cells is similar to the one described for CTLs
although it has some particularities (Davis et al., 1999; Krzewski
and Strominger, 2008). Two different IS have been named, the
activating IS and the inhibitory IS. Activating IS is formed by a
FIGURE 2 | Schematic showing the role of PKCθ in anti-tumoral NK cell
activation. Upper panel, situation in NK cells from wild-type (wt) mice:
cytokines produced by macrophages and/or dendritic cells upon poly I:C
activation, or upon the sensing of tumor “danger” signals, including IL-15,
induce the activation of NK cells through signaling dependent on PKC-θ (black
arrows). This activation increases the cytotoxic potential of NK cells that can
lyse tumoral target cells, especially those that are negative for MHC-I
expression, and prevent tumor development. In addition, the production of
TNF-α and IFN-γ by NK cells induced by certain killer-activating receptors (KAR)
is also dependent on PKC-θ (red arrows), allowing the recruitment of more
immune cells and sustaining immune activation. Lower panel, situation in NK
cells from PKC-θ−/− mice: as a consequence of the absence of PKC-θ,
cytokines produced by macrophages and/or dendritic cells do not activate
properly NK cells, which then show a defect in lysis of tumoral cells, allowing
tumoral development. In addition, the production of TNF-α and IFN-γ by NK
cells is decreased, causing defects in recruitment.
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central supramolecular activating cluster (SMAC) where all recep-
tors involved in signal transduction accumulate and a peripheral
SMAC where the adhesion molecule LFA-1 is placed. Similarly,
inhibitory receptors accumulate in the cSMIC and LFA-1 in the
pSMIC (Carlin et al., 2001). However, given the different number
of activating and inhibitory receptors (see Natural Killer Cells),
the molecular mechanisms regulating signaling from the synapse
is more complex than in the case of other lymphocytes subsets
like CTLs (Vyas et al., 2002a; Krzewski and Strominger, 2008).
Specifically, formation and signaling through IS in NK cells is
dynamically regulated by activation thresholds dictated by the
balance between activating and inhibitory receptors. Most of the
studies have characterized the IS formed after engagement of target
cells by the activating NKG2D receptor (Krzewski and Strominger,
2008). However, as explained above, signaling from NKG2D recep-
tors is regulated differentially from other receptors. Formation of
the NK cell IS is regulated at different stages (Orange et al., 2003).
The first stage implies an activation process after target cell engage-
ment, followed by signal amplification and the rearrangement of
the actin cytoskeleton in the pSMAC. This process is regulated by
the WASP protein. Subsequently, MTOC is polarized and granule
content is released through the cSMAC, as in the case of CTLs. All
these activation steps are negatively regulated by signaling trans-
duced by SHP phosphatases from inhibitory receptors (Krzewski
and Strominger, 2008).
MOLECULES REGULATING CTL AND NK CELL DEGRANULATION
The molecular defects responsible of several diseases have allowed
the identification of important molecules implicated in CTL
degranulation (Clark and Griffiths, 2003; Stinchcombe and Grif-
fiths, 2007; de Saint Basille et al., 2010). Granule movement
through tubulin filaments is regulated by the adaptor protein-4
(AP-3; Clark et al., 2003), docking onto the plasma membrane
is regulated by Rab27a (Haddad et al., 2001; Stinchcombe et al.,
2001a), and priming or fusion with the membrane by Munc-13-4
(Feldmann et al., 2003). Finally, ASMAse is involved in the proper
shrinkage of secretory granules after docking and priming steps
to efficiently release granule content into target cells (Herz et al.,
2009).
Regarding NK cells, it has been demonstrated that myosin
IIA and WIP are required for granule polarization and NK cell-
mediated cytotoxicity (Krzewski et al., 2006). Moreover, it could
be suggested that Munc-13-4 is also involved in NK cell granule
exocytosis since patients deficient in this protein present deficient
NK cell-mediated cytotoxicity (Marcenaro et al., 2006; Bryceson
et al., 2007). Syntaxin-11 also participates in the fusion of gran-
ules with the membrane of human NK cells (Arneson et al., 2007;
Bryceson et al., 2007).
TCR EARLY SIGNALING DURING CTL DEGRANULATION. IMPLICATION
OF PKC ISOFORMS
Although the most important regulators of lytic granule exocy-
tosis are well described, at least in CTL, the connection between
activating receptor-triggered signal transduction and lytic granule
secretion is not completely understood. In the case of CTL, TCR
signal transduction is initiated through protein tyrosine kinases of
the src family that, together with the action of recruited ZAP-70
results in the phosphorylation and activation of phospholipase C-
γ1 (Mustelin et al., 1990; Chan et al., 1992). CTL degranulation
depends on these tyrosine kinase-mediated signaling pathways
(Secrist et al., 1991; O’Rourke and Mescher, 1992; Anel and Kle-
infeld, 1993). PLC-γ activation produces diacyl glycerol (DAG),
which activates PKCs, and inositol-trisphosphate (IP3), which
increases the intracellular Ca++ concentration. A combination
of the phorbol ester phorbol myristate-acetate (PMA) and the
calcium ionophore ionomycin induces CTL degranulation. Gran-
ule movement was dependent on Ca++ and CTL shape change
was dependent on PKC activity (Takayama and Sitkovsky, 1987;
Haverstick et al., 1991). Depletion of PMA-sensitive PKC isoforms
by prolonged PMA exposure prevented TCR-induced degranula-
tion in CTL clones (Nishimura et al., 1987; Anel et al., 1994). In
addition, PKC inhibition prevented MTOC polarization in CTL
(Nesic et al., 1998).
A closer look at the role of individual PKC isoforms in CTL
function revealed that PKCθ was implicated in the induction of
FasL expression at a transcriptional level (Villalba et al., 1999; Vil-
lunger et al., 1999; Pardo et al., 2003). This is probably due to the
role of PKCθ in NF-AT and NF-κB activation (Sun et al., 2000;
Pfeifhofer et al., 2003), transcription factors which are involved in
the control of FasL gene transcription (Latinis et al., 1997; Kasibh-
latla et al., 1999). As already commented above, PKCθ is the only
PKC isoform that is activated through a PI3K-dependent path-
way that is triggered by TCR ligation (Villalba et al., 2002). This
is in agreement with the fact that functional FasL expression is
also prevented by PI3K inhibitors in long-term CTL clones (Anel
et al., 1995; Pardo et al., 2003). Perforin/granzyme mediated lysis
of Fas-negative target cells and CTL degranulation is sensitive to
broad-spectrum PKC inhibitors, and also to Gö-6976, a specific
inhibitor of the classical PKC isoforms (α, β, γ), but not to low
doses of rottlerin, an inhibitor that prevents PKCθ activation (Vil-
lalba et al., 1999; Pardo et al., 2003). In addition, transfection
with constitutively active PKCα, but not with PKCθ, cooperated
with ionomycin to promote degranulation in murine CTL clones
(Pardo et al., 2003). Later works demonstrated that both consti-
tutively active PKCα and PKCθ cooperated with thapsigargin to
induce degranulation in a human CTL tumoral cell line, although
PKCα seemed more efficient (Grybko et al., 2007).
DOWNSTREAM SIGNALING DURING CTL DEGRANULATION
Cytotoxic T lymphocyte and NK cell degranulation is depen-
dent on both actin cytoskeleton and on tubulin microtubules
(Gomez and Billadeau, 2008). The proximal signaling described
above connects initially with remodeling of the actin cytoskele-
ton mainly through the adaptors Vav1 and SLP76 (Villalba et al.,
2001a; Zeng et al., 2003). These actin cytoskeleton remodeling
events are needed for immune synapse formation in CD4+ T
cells, in CTL and also in NK cells. Once the immune synapse
is formed, the next step for degranulation to occur is MTOC
polarization (Kuhn and Poenie, 2002). Once MTOC is polarized,
granules should move on tubulin rails, dock to the plasma mem-
brane, and fuse to release their content in the IS. For these steps
to occur, the granule and membrane proteins described above are
needed, but signaling events are not completely elucidated. A role
for ERK activation in CTL degranulation was clearly established
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(Berg et al., 1998). This activation was dependent on PI3K, and
paxillin has been identified as the ERK substrate that mediates
MTOC polarization to the IS (Robertson et al., 2005; Robertson
and Ostergaard, 2011). However, a role for PKCθ in ERK activation
was not clearly demonstrated, and primary CTL from PKCθ−/−
mice degranulated normally (Puente et al., 2006).
EARLY SIGNALING DURING NK CELL DEGRANULATION
Regarding NK cell degranulation elicited by KARs, signal trans-
duction pathways are similar to those described in CTL in the case
of those receptors that use FcεR1γ, CD3ζ, or DAP12 adaptors, but
different in receptors that use DAP10 or SAP adaptors, such as
NKG2D and CD244, respectively. However, by activating the PI3K
pathway and the PLCγ-mediated increase in intracellular calcium
concentration in the case of NKG2D and by the SAP-mediated
activation of the protein tyrosine kinase Fyn in the case of CD244,
these KAR arrive to generate similar downstream signaling that
leads finally to degranulation (Cerwenka and Lanier, 2001; Lanier,
2008). In fact, it has been demonstrated that mouse NK cells do
not require Syk and ZAP-70 kinases to kill different types of tar-
get cells, even those that do not express ligands for NKG2D, and
that only abrogating at the same time the activity of src kinases
and PI3K, degranulation was prevented (Colucci et al., 2002). In
addition, the consequences of signaling transduced by the differ-
ent receptors do not seem to be redundant. It has been previously
shown that not a single activating receptor is sufficient to induce
NK cell-mediated cytotoxicity against target cells (Bryceson et al.,
2006). Only certain synergistic combinations of receptors are able
to trigger this process. For example, it has been shown that engage-
ment of CD16 induces degranulation in a non-polarized manner,
meanwhile engagement of LFA-1 was able to polarize granules
toward the IS. However, only after simultaneous engagement of
both molecules NK cells were able to kill target cells (Bryceson
et al., 2005), indicating also the importance of adhesión receptors
such as LFA-1.
DOWNSTREAM SIGNALING DURING NK CELL DEGRANULATION.
IMPLICATION OF PKC
Regarding downstream signaling in NK cell degranulation, it has
been clearly demonstrated that the PI3K-mediated activation of
ERK is involved in NK cell degranulation elicited by CD16 (Bon-
nema et al., 1994), by KARs that use DAP12 (Jiang et al., 2000,
2002) and also by those using DAP10 as adaptor (Billadeau et al.,
2003; Upshaw et al., 2006). ERK activation results finally in MTOC
polarization, similarly to what was observed in CTL degranulation
(Chen et al., 2006). In the case of NKG2D, the PI3K pathway also
results in the recruitment of the adaptor CrkL, needed for efficient
MTOC polarization (Segovis et al., 2009). A role for JNK activa-
tion has been also demonstrated in NKG2D-mediated cytotoxicity
(Li et al., 2008).
The role of PKC in NK cell degranulation was initially demon-
strated since a combination of PMA and ionomycin is able to
induce degranulation in these cells (Bonnema et al., 1994). It was
also demonstrated that DNAM-1 signal transduction is depen-
dent on PKC expression (Shibuya et al., 1998). Less is known
about the role of different PKC isoforms in NK cell degranula-
tion. As mentioned above, PKCθ is expressed by NK cells. During
activation of the human NK cell line YTS with target cells with no
HLA-I expression, a PKCθ pseudo-substrate inhibitor prevented
WIP phosphorylation (Krzewski et al., 2006). WIP forms a com-
plex with WASP and myosin IIA that regulates actin cytoskeleton
dynamics during NK cell activation, and WIP knockdown prevents
NK cell degranulation (Krzewski et al., 2008). However, it was not
demonstrated that the formation of this complex was dependent
on WIP phosphorylation by PKCθ (Krzewski et al., 2006). Inter-
estingly, it has been recently published the kinome of NK cells
activated by CD16 or simultaneous CD244 and DNAM-1 liga-
tion, being PKC-θ identified as the only PKC isoform that increase
phosphorylation upon receptor ligation (König et al., 2012).
The results described above, most of them obtained in CTL,
suggest that PKCθ is not mandatory for granule exocytosis. How-
ever, it has not been studied yet in detail its possible involvement
in NK cell immune synapse signaling and in NK cell granule
polarization and/or secretion.
CONCLUSION
PKCθ plays an important role in tumor immune surveillance
in vivo (Garaude et al., 2008; Aguiló et al., 2009). In the case of
CTL-mediated tumor control, this can be explained by its role as
a CTL survival factor (Barouch-Bentov et al., 2005), the impaired
cytokine response observed in PKCθ deficient animals (Sun et al.,
2000) and its implication in FasL expression (Villalba et al., 1999;
Villunger et al., 1999; Pardo et al., 2003).
In the case of NK cell-mediated tumor control, several func-
tional consequences of PKCθ deficiency can also contribute to
FIGURE 3 | Schematic showing possible mechanisms for the role of
PKCθ in NK cell-mediated anti-tumor immunity.The following working
hypothesis are formulated (see the text for details): (A) cytokines produced
by macrophages and/or dendritic cells, by signaling through PKC-θ, increase
granzyme B expression. An increase in granzyme B expression is directly
associated with the augmentation of the cytolytic potential of NK cells; (B)
cytokines produced by macrophages and/or dendritic cells, by signaling
through PKC-θ, induce or increase the expression of a protein (X) implicated
in degranulation of NK cells; (C) PKC-θ could be directly implicated in
degranulation of NK cells through specific KARs.
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the final outcome. As depicted in the schematic Figure 2, KAR-
induced TNF-α and IFN-γ secretion is defective in PKCθ−/− mice
(Tassi et al., 2008), and this can contribute to a defective recruit-
ment of effector cells to the site of tumor development (Aguiló
et al., 2009). Also, PKCθ could be implicated in the induction of
FasL expression (Pardo et al., 2003), although this has not been
demonstrated in NK cells. In addition, the possibilities shown in
Figure 3 may be considered, although they should be taken as
working hypothesis that need to be better characterized:
a) Macrophage or dendritic cell derived cytokines, through a
pathway that implicates PKCθ, induce an increase in granzyme
B expression.
b) Macrophage or dendritic cell derived cytokines, through a
pathway that implicates PKCθ, induces or increases the expres-
sion of a cellular component (X) that is needed to increase the
degranulation potential of NK cells.
c) PKCθ is directly implicated in NK cell degranulation elicited
by specific KARs.
These three possibilities are not mutually exclusive, and all of
them can contribute to the regulation of NK cell anti-tumoral
potential. In addition, different signaling and/or functional
responses can be activated by different KARs, and PKC-θ could
be relevant for signaling elicited by some KARs but not by others.
Undoubtedly, uncovering the precise molecular mechanisms that
direct these processes will allow a rational improvement of NK
cell-mediated anti-tumor immunotherapy protocols.
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